Red Sky Partners is a team of
biotechnology industry veterans:
- Lead negotiator on more than 100 licensing, partnering and M&A life sciences deals, including managing the selling, buying and diligence processes.
- Headed business development, legal and IP functions at private and public biotech companies, including during private and IPO financings.
- Previously held CBO and senior management roles at Domantis, Dyax, Avant and Biogen, and has been a business strategy consultant for several biotech companies.
- Co-founder and President, Visgo Therapeutics, Inc.
- BA in Biology from Cornell University; JD from the University of Wisconsin School of Law
- Executive responsibility for assessment, due diligence and execution of significant business transactions as seller or buyer and led closure of numerous private and public financings.
- Extensive experience in global product development, approval and launch.
- Prior C-level and EVP positions at Genzyme, Haemonetics, Cyberkinetics and BioSurface Technology.
- Current Board member and Audit committee chair at NeuroMetrix; Director, Precision Ventures.
- BA in Biochemistry from Williams College; MBA from Harvard Business School
Pauline Jen Ryan
Tim’s 25 year career in biotechnology, cell therapy and medical device general management includes experience as a founder of three start-up companies as well as senior executive assignments at two of Massachusetts’ top 20 healthcare companies. In these roles he has had extensive line management experience with a particular focus on business development transactions, new product development and launch, investor relations and corporate finance.
Prior to founding Red Sky Partners in early 2009, Tim was President and CEO of Cyberkinetics NeuroTechnology Systems, Inc. His previous positions include EVP of Haemonetics Corporation, President of Genzyme Tissue Repair, the cell therapy division of Genzyme Corporation, and EVP and CFO of BioSurface Technology. Tim serves on the Board of Directors of NeuroMetrix, Inc., a medical device company, and the Charles River School in Dover, MA. Tim received a B.A. in Biochemistry from Williams College and an M.B.A. from Harvard Business School.
Lead negotiator on over 75 licensing, collaboration, service and supply agreements, including the deal that resulted in the commercialization of Kadcyla® for metastatic breast cancer
Headed corporate strategy, business and corporate development, alliance management, IP, manufacturing/supply chain management and all business operations functions including finance, human resources and communications at public and private biotech companies
Previously held C-level roles at Proteostasis and ImmunoGen; other experience includes BD at Organogenesis and sales/marketing consulting
Startup experience includes current CEO role at Verik Bio and working with lead VC to launch Proteostasis Therapeutics
BA in Psychology from Northwestern University; MBA from Kellogg Graduate School of Management, Northwestern University
Richard Douglas, Ph.D.
Mason "Skip" Irving
- For over 30 years, advised senior management teams, boards of directors and investors in the life sciences at Health Advances LLC and Arthur D. Little, Inc. focusing on business strategy, product commercialization, R&D planning, financing and business development
- Expert in guiding strategic planning processes and facilitating management strategy sessions
- Currently serves part time as Vice President for development-stage biotherapeutics company Stemnion, Inc.
- Currently serves on the Board of Directors of the Michael J. Fox Foundation for Parkinson’s Research, Board of Overseers for Mt. Auburn Hospital and the College Corporation at The Massachusetts College of Pharmacy and Allied Health Sciences
- Adjunct Professor at the University of New England Center for Excellence in Neuroscience
- Founding investor in t-Breeders, Inc., a cellular therapy company eventually sold to Perkin Elmer
- BS in Pharmacy and MBA from the Tuck School at Dartmouth College